Equities research analysts forecast that Opko Health Inc. (NASDAQ:OPK) will post sales of $262.52 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Opko Health’s earnings. The lowest sales estimate is $259.67 million and the highest is $268.10 million. Opko Health posted sales of $263.50 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.4%. The company is expected to issue its next quarterly earnings results on Wednesday, November 14th.

On average, analysts expect that Opko Health will report full-year sales of $1.04 billion for the current year, with estimates ranging from $1.03 billion to $1.05 billion. For the next fiscal year, analysts anticipate that the business will report sales of $1.07 billion, with estimates ranging from $1.03 billion to $1.09 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The business had revenue of $263.69 million for the quarter, compared to the consensus estimate of $260.37 million.

A number of equities research analysts have issued reports on OPK shares. BidaskClub upgraded Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 3rd. ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, July 26th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $20.00 price objective on shares of Opko Health in a research report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Opko Health presently has an average rating of “Hold” and a consensus price target of $9.69.

In other Opko Health news, CEO Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock in a transaction dated Tuesday, July 3rd. The shares were purchased at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $14,577,517.25. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders bought 280,220 shares of company stock worth $1,514,311. Company insiders own 42.74% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of OPK. BlackRock Inc. raised its holdings in shares of Opko Health by 38.7% in the second quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after buying an additional 8,237,434 shares during the period. Northern Trust Corp raised its holdings in shares of Opko Health by 129.9% in the second quarter. Northern Trust Corp now owns 4,025,496 shares of the biotechnology company’s stock worth $18,920,000 after buying an additional 2,274,820 shares during the period. Millennium Management LLC raised its holdings in shares of Opko Health by 95.6% in the first quarter. Millennium Management LLC now owns 2,178,877 shares of the biotechnology company’s stock worth $6,907,000 after buying an additional 1,065,216 shares during the period. RK Asset Management LLC purchased a new stake in shares of Opko Health in the second quarter worth approximately $4,822,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Opko Health by 49.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 2,395,831 shares of the biotechnology company’s stock worth $11,261,000 after buying an additional 788,753 shares during the period. Hedge funds and other institutional investors own 24.78% of the company’s stock.

Shares of OPK stock opened at $3.72 on Thursday. Opko Health has a 1 year low of $2.66 and a 1 year high of $7.24. The company has a current ratio of 1.05, a quick ratio of 0.90 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -12.83 and a beta of 2.09.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Featured Story: Do closed-end mutual funds pay dividends?

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.